Hilleman’s Pioneering Shigella Vaccine Set For First Trials
India’s Hilleman Laboratories, in partnership with a government agency, expects to start human trials this year with a pioneering multivalent vaccine to prevent shigellosis, a highly contagious bacterial diarrheal disease that is a major killer of children in low-income countries but has proven a difficult vaccine target.
You may also be interested in...
India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.
Indian vaccine research organization Hilleman Laboratories says it is hoping to get its "new design", cheaper cholera vaccine licensed in Bangladesh this year and that the next step will be to seek to make it available to UN agencies amid remaining global inoculation need.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.